1. Trang chủ
  2. » Luận Văn - Báo Cáo

Tài liệu Báo cáo khoa học: High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose pptx

15 486 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Tiêu đề High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptor
Tác giả Michelle A. Hartman, Jodi L. Kreiling, James C. Byrd, Richard G. MacDonald
Trường học University of Nebraska Medical Center
Chuyên ngành Biochemistry and molecular biology
Thể loại Article
Năm xuất bản 2009
Thành phố Omaha
Định dạng
Số trang 15
Dung lượng 361,37 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Pairing of wild-type and point-mutated IGF-II binding sites between two dimerized mini-receptors had no effect on the function of the contralateral binding site, indicating IGF-II bindin

Trang 1

heteromeric complexes of the mannose

6-phosphate/insulin-like growth factor II receptor

Michelle A Hartman1, Jodi L Kreiling2, James C Byrd1and Richard G MacDonald1

1 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

2 Department of Chemistry, University of Nebraska, Omaha, NE, USA

The mannose 6-phosphate⁄ insulin-like growth factor II

receptor (M6P⁄ IGF2R) is a 300 kDa transmembrane

glycoprotein that has diverse ligand-binding properties

contributing to several important cellular functions

[1,2] Insulin-like growth factor II (IGF-II) binding to the M6P⁄ IGF2R leads to uptake into the cell and deg-radation of the growth factor in lysosomes [3–6] This activity reduces IGF-II availability in the pericellular

Keywords

insulin-like growth factor II; ligand binding;

mannose 6-phosphate; mannose

6-phosphate ⁄ insulin-like growth factor II

receptor; oligomerization

Correspondence

R G MacDonald, Department of

Biochemistry and Molecular Biology,

University of Nebraska Medical Center,

985870 Nebraska MED CTR, Omaha, NE

68198 5870, USA

Fax: +1 402 559 6650

Tel:+1 402 559 7824

E-mail: rgmacdon@unmc.edu

(Received 17 October 2008, revised 19

December 2008, accepted 21 January 2009)

doi:10.1111/j.1742-4658.2009.06917.x

The mannose 6-phosphate⁄ insulin-like growth factor II receptor has diverse ligand-binding properties contributing to its roles in lysosome biogenesis and growth suppression Optimal receptor binding and internalization of mannose 6-phosphate (Man-6-P)-bearing ligands requires a dimeric struc-ture leading to bivalent high-affinity binding, presumably mediated by cooperation between sites on both subunits Insulin-like growth factor II (IGF-II) binds to a single site on each monomer It is hypothesized that IGF-II binding to cognate sites on each monomer occurs independently, but bivalent Man-6-P ligand binding requires cooperative contributions from sites on both monomers To test this hypothesis, we co-immunopre-cipitated differentially epitope-tagged soluble mini-receptors and assessed ligand binding Pairing of wild-type and point-mutated IGF-II binding sites between two dimerized mini-receptors had no effect on the function of the contralateral binding site, indicating IGF-II binding to each side of the dimer is independent and manifests no intersubunit effects As expected, heterodimeric receptors composed of a wild-type monomer and a mutant bearing two Man-6-P-binding knockout mutations form functional IGF-II binding sites By contrast to prediction, such heterodimeric receptors also bind Man-6-P-based ligands with high affinity, and the amount of binding can be attributed entirely to the immunoprecipitated wild-type receptors Anchoring of both C-terminal ends of the heterodimer produces optimal binding of both IGF-II and Man-6-P ligands Thus, IGF-II binds indepen-dently to both subunits of the dimeric mannose 6-phosphate⁄ insulin-like growth factor II receptor Although wild-type⁄ mutant hetero-oligomers form readily when mixed, it appears that multivalent Man-6-P ligands bind preferentially to wild-type sites, possibly by cross-bridging receptors within clusters of immobilized receptors

Abbreviations

Glc-6-P, glucose 6-phosphate; HA, hemagglutinin; HBS, Hepes-buffered saline; HBST, HBS containing 0.05% Triton X-100; IGF-II, insulin-like growth factor II; M6P ⁄ IGF2R, mannose 6-phosphate ⁄ insulin-like growth factor II receptor; Man-6-P, mannose 6-phosphate; pBSKII+, pBluescript SK II+; PMP-BSA, pentamannosyl 6-phosphate-BSA.

Trang 2

milieu, thereby decreasing its binding to mitogenic

IGF-I receptors, which contributes substantially to the

function of the M6P⁄ IGF2R as a growth or tumor

suppressor Binding of lysosomal enzymes by the

receptor is mediated by mannose 6-phosphate

(Man-6-P) groups on N-linked oligosaccharides, and this

mechanism is critical to lysosome biogenesis [7] There

are also a number of glycoproteins other than the

lyso-somal enzymes that bind to the receptor by a

Man-6-P-dependent mechanism, including thyroglobulin,

proliferin, granzyme B and latent transforming growth

factor-b [1,2,8] Several ligands, such as retinoic acid,

urokinase-type plasminogen activator receptor and

plasminogen, have also been reported to interact with

the M6P⁄ IGF2R via novel binding sites [9–13]

The human M6P⁄ IGF2R consists of a large

extracy-toplasmic domain (ectodomain) of 2265 amino acid

residues, a 23-residue transmembrane domain, and a

short, 164-residue cytoplasmic domain [14,15] The

ectodomain comprises fifteen repeats having 14–28%

sequence identity Each of the repeats is formed by a

disulfide-bonded, crossed antiparallel b-sheet sandwich

that resembles a flattened b-barrel [16] Ligand binding

experiments have mapped the Man-6-P binding

domains mainly to repeats 3 and 9, wherein mutation

of critical residues can reduce ligand affinity [17], and

such mapping is in agreement with the structure of

repeat 3 deduced from X-ray crystallography [18] The

main amino acid residues involved in IGF-II binding

are located within repeat 11, but residues within repeat

13 cooperate with repeat 11 to enhance ligand binding

affinity [19–22]

Until recently, the M6P⁄ IGF2R was considered to

be monomeric in structure, and this view was

sup-ported by studies on the physicochemical properties

of the solubilized receptor [23] However, a recent

study by York et al [24] demonstrated that

phos-phomannosyl ligands with multiple Man-6-P moieties,

such as b-glucuronidase, induced the cell-surface

M6P⁄ IGF2R to form dimers, which enhanced the

rate of receptor internalization These studies

provided the first evidence of ligand-mediated

cross-bridging of receptor monomers into a dimeric

struc-ture that interacted with apparently increased

efficiency with the endocytic apparatus IGF-II

bind-ing failed to produce such an increase in receptor

internalization, which supported the hypothesis that

IGF-II binds to its sites on the individual monomeric

receptors [24] Further insight into the mechanism of

dimerization was provided by Byrd et al [25], who

showed that dimer formation could occur

indepen-dently of ligand binding, presumably mediated by

direct interactions between the ectodomains of each

monomer Kreiling et al [26] found that there is not

a specific M6P⁄ IGF2R dimerization domain but, rather, there are interactions that exist between dimer partners all along the ectodomain of the receptor Collectively, these studies led to the hypothesis that production of high-affinity ligand binding arises from cooperation between Man-6-P binding sites on each monomeric partner [1,27] The dimer-based model for high-affinity Man-6-P binding has recently received support from structural analysis of repeats 1–3 of the receptor’s ectodomain by Olson et al [18] Although binding of IGF-II by the M6P⁄ IGF2R does not induce receptor dimerization [24] and it is known that IGF-II binds the receptor with one-to-one stoichiome-try [28], it remains unknown whether dimerization of the receptor has any effect on IGF-II binding That

is, would a defective IGF-II binding site on one monomer interfere with IGF-II binding on the other monomer?

The present study aimed to test the hypothesis that IGF-II binds independently to its binding sites

on each receptor monomer, but that Man-6-P ligand binding is bivalent, requiring cooperative interaction

of cognate sites on both monomers of the dimeric receptor To test this hypothesis, we measured ligand binding by dimers formed from cDNA constructs encoding repeats 1–15 of the M6P⁄ IGF2R ectodo-main Our co-immunoprecipitation data indicate that oligomer formation does occur between receptors bearing different C-terminal epitope tags Hetero-dimeric receptors composed of a wild-type monomer and a mutant bearing an IGF-II binding knockout mutation can form fully functional phosphomannosyl binding sites By contrast, such receptor dimers are capable of binding IGF-II to the wild-type side, but not to the mutant side of the dimer Overall, the analysis of IGF-II binding in such receptor dimers suggests that each half of the dimer is capable of binding IGF-II independently of the ligand occupancy of the contralateral site A heterodimeric receptor composed of a wild-type monomer and a mutant bearing two Man-6-P binding knockout mutations can form functional IGF-II binding sites However, such receptors are also capable of high-affinity Man-6-P binding, with the amount of ligand binding being directly proportional to the amount of the wild-type receptor present These results can be explained either by a sterically improbable intramolecular binding mechanism or by binding of a multivalent ligand forcing receptors to realign within the immunoprecipitated complexes, thus promoting preferential cross-bridging between wild-type receptors

Trang 3

Transient expression and ligand binding

properties of FLAG and Myc epitope-tagged

M6P/IGF2R mini-receptors

The M6P⁄ IGF2R ectodomain is critical for receptor

ligand binding and dimerization [19,25,29,30]

There-fore, receptor constructs for testing these functions

were designed to encode all 15 repeats of the

ectodo-main of the M6P⁄ IGF2R followed by either an

eight-residue FLAG epitope tag or a 12-eight-residue Myc tag

(Fig 1A) Distinct epitope tags were used to allow

detection of heterologous interactions between

mini-receptors Two forms of the FLAG and Myc

epitope-tagged mini-receptors, 1-15 wild-type and 1-15 I1572T

(I⁄ T), were transiently expressed alone or co-expressed

in HEK 293T human embryonic kidney cells Cell extracts were prepared using Triton X-100 and analyzed for relative expression levels of the mini-receptors by immunoblotting with M2 anti-FLAG or 9E10 anti-Myc immunoglobulins (Igs) (data not shown)

The two differentially tagged mini-receptors were constructed to assess the possibility of intersubunit effects between receptors Several studies have deter-mined that the I1572T mutation residing in the heart

of the IGF-II binding domain in repeat 11 disrupts IGF-II binding to the receptor [22,31–33] The ligand blotting data shown in Fig 1C confirm that the wild-type mini-receptors used in the present study could bind IGF-II, whereas the I⁄ T mutant mini-receptors could not By contrast, both wild-type and mutant mini-receptors bound the phosphomannosylated pseudoglycoprotein pentamannosyl 6-phosphate-BSA (PMP-BSA) (Fig 1B) The presence of the different epitope tags on the mini-receptors had no apparent effect on ligand binding in this assay

Ligand binding by immunoprecipitated FLAG-tagged M6P/IGF2R mini-receptors Previous studies suggested the possibility of negative cooperativity of ligand binding by the oligomeric M6P⁄ IGF2R [34] Thus, prior to examination of FLAG- and Myc-tagged mini-receptors, we assessed the ligand binding characteristics of a mixture of wild-type and mutant FLAG-tagged mini-receptors To accomplish this, cells were transfected with a mixture

of cDNAs in which the proportion of mutant cDNA

to wild-type cDNA was increased, whereas the total amount of cDNA was held constant The effects of the

I⁄ T mutation on both IGF-II and PMP-BSA binding were analyzed using FLAG-tagged mini-receptors in a mixed immunoprecipitation, which ensured that both C-terminal ends were anchored to the resin in the same way (Fig 2) Binding of [125I]PMP-BSA to mixed mini-receptors, which was measured to establish a baseline of ligand binding function, was not affected

by the proportion of wild-type to mutant mini-recep-tor, suggesting that the I⁄ T mutation did not interfere with functional phosphomannosyl ligand binding (Fig 2A) Binding of [125I]IGF-II to immunoprecipi-tated mini-receptors was measured to assess if IGF-II binds the wild-type mini-receptor in the presence of the I⁄ T mutant mini-receptors (Fig 2B) It was pre-dicted that the presence of the I⁄ T mutant mini-recep-tors would not interfere with IGF-II binding to the wild-type receptors because IGF-II is a monovalent ligand that should bind independently to each

avail-Myc

FLAG

FLAG

Myc

COOH

COOH

COOH

COOH

H

H 2 N

H 2 N

H 2 N

*

*

Construct name:

1-15F

1-15F I/T

1-15Myc

1-15Myc I/T

3

5 1- 1 F 1-15F

I/T -15 1 My c 1-15 M c T y /

IGF-II

Endogenous

A

B

C

Fig 1 Schematic diagram and ligand blot analysis of FLAG and

Myc epitope-tagged M6P⁄ IGF2R mini-receptors (A) The receptor

constructs are shown in linear format from the amino terminus to

the carboxyl terminus, with repeats of the ectodomain shown as

rectangles The shaded rectangles indicate repeats 3 and 9, to

which the main determinants of Man-6-P binding have been

mapped The stippled rectangles represent repeat 11 containing

the principal residues responsible for IGF-II binding, and the

aster-isk denotes the I>T mutation at residue 1572 (I ⁄ T), which

abro-gates IGF-II binding The black rectangles represent the FLAG or

Myc epitope tags on the carboxyl terminus (B, C) Equimolar

amounts of the transfected cell lysates were electrophoresed on

6% nonreducing SDS⁄ PAGE gels The proteins were transferred to

BA85 nitrocellulose, processed for ligand blotting and probed for

binding of either [125I]PMP-BSA (B) or [125I]IGF-II (C) and developed

by autoradiography The autoradiograms of representative blots are

shown.

Trang 4

able receptor [24] The data shown in Fig 2B support

this idea because the total amount of IGF-II binding

tended to follow the line displayed in the bar graph,

which was calculated based on the percentage of

wild-type versus mutant receptor cDNAs input into the

original transfection (Fig 2B)

Ligand binding by co-immunoprecipitated

FLAG- and Myc-tagged M6P/IGF2R mini-receptors

To determine whether co-transfected mini-receptors

interact in a possible oligomeric complex, 293T cell

lysates containing co-expressed FLAG and Myc

epitope-tagged mini-receptors were analyzed by an immunoprecipitation assay using M2 anti-FLAG affinity resin The resin pellets were washed to remove unbound proteins, separated by reducing SDS⁄ PAGE, and analyzed by immunoblotting with anti-FLAG or anti-Myc Igs to determine whether the Myc epitope-tagged mini-receptors interacted with the FLAG epitope-tagged mini-receptors (Fig 3A–D) Cells were transfected either with 30 lg of cDNA encoding the FLAG- and Myc-tagged mini-receptors alone or with

a combination of 15 lg of each differentially tagged mini-receptor cDNA PhosphorImager analysis of the blots revealed that essentially all of the expressed FLAG-tagged mini-receptors precipitated by incuba-tion with the M2 affinity resin (Fig 3A versus B) If the level of expression of mutant versus wild-type receptors reflects the proportion of their respective cDNAs in the transfection, and based on random asso-ciation to form dimers, it was projected that co-immu-noprecipitation of the FLAG-tagged mini-receptors from a 1 : 1 transfection pool would yield a 1 : 2 : 1 distribution of wild-type homodimers, wild-type⁄ mutant heterodimers and mutant homodimers, respec-tively Figure 3C,D indicates that approximately 50%

of the co-expressed Myc-tagged mini-receptors were co-immunoprecipitated with the FLAG-tagged mini-receptors (Fig 3C versus D), suggesting that approxi-mately half the Myc-tagged mini-receptors existed as homodimers (which do not precipitate in this assay) and the other half formed heterodimers with the FLAG-tagged mini-receptors Figure 3C,D indicates that the Myc-tagged mini-receptor did not immuno-precipitate in the absence of a FLAG-tagged partner

In addition, it is noteworthy that the presence of the

I⁄ T mutation had no apparent effect on the interaction leading to co-immunoprecipitation

These data indicate that differentially epitope-tagged M6P⁄ IGF2R mini-receptors were capable of associa-tion as asymmetric oligomers, but they do not indicate whether these structures are functional in ligand bind-ing To test this property, co-immunoprecipitated mini-receptors were subjected to direct binding analysis using radiolabeled ligands (Fig 3E,F) For this pur-pose, differentially tagged mini-receptors were co-immunoprecipitated using a FLAG-based antibody from lysates of cells transfected with a 1 : 1 ratio of receptor cDNAs We would expect that approximately 25% of the Myc-tagged mini-receptors would be pres-ent as homodimers, and thus would not precipitate in this assay Thus, it was projected that PMP-BSA bind-ing to the co-immunoprecipitated mini-receptors would yield approximately 75% of the binding observed with individually immunoprecipitated FLAG-tagged

mini-0

30

30

µg 1-15F cDNA

µg 1-15I/T cDNA

0

0

25

50

75

100

125

150

I-IGF-II binding c.p.m × 10

0

10

20

30

40

A

B

Fig 2 Analysis of ligand binding to soluble 1-15 and 1-15 I ⁄ T

mutant FLAG epitope-tagged receptors immunoprecipitated with

anti-FLAG resin Cell lysates, containing equimolar amounts of

expressed soluble receptors, were immunoprecipitated with M2

anti-FLAG affinity resin and assayed for binding of [ 125 I]PMP-BSA

(A) or [ 125 I]IGF-II (B) The lines in each graph indicate the amount of

binding predicted if the wild-type and mutant receptors are binding

ligand independently The triangles indicate a progressive shift in

the ratio of wild-type to mutant receptor cDNA transfected into

cells Values represent the mean ± SD of three replicate

measure-ments for each condition These data represent the means of four

independent experiments [Correction added on 5 March 2009 after

first online publication: in Fig 2B ‘ 125 I-PMP-BSA binding’ was

cor-rected to ‘125I-IGF-II binding’.]

Trang 5

receptors (Fig 3E) Binding of [125I]PMP-BSA to

immunoprecipitated mini-receptors was not affected by

the proportion of wild-type versus I⁄ T mutant

mini-receptors in the mixture, suggesting that the I⁄ T

muta-tion did not interfere with the formamuta-tion of oligomers

that are functional in phosphomannosyl ligand binding

and establishing a baseline of ligand binding function

(Fig 3E)

Binding of [125I]IGF-II to immunoprecipitated

mini-receptors was measured to assess whether IGF-II binds

independently to the asymmetric heterodimers

(Fig 3F) In this assay, we expected that 25% of the

dimers formed would be Myc-tagged symmetric

homodimers and therefore would not be

immuno-precipitated by the M2 resin, 25% would be

FLAG-tagged symmetric homodimers, and the remaining 50% of the dimers formed would be FLAG- and Myc-tagged asymmetric heterodimers The calculations projected that the percentage of binding would follow the line displayed in the bar graph However, the data show that when a mutant FLAG-tagged mini-receptor served as the ‘bait’ for immunoprecipitation, binding

of IGF-II to the asymmetric heterodimers was sup-pressed or not detected as readily as expected One possibility for explaining this functional deficit may comprise interference from the pairing of two different C-terminal epitope tags

Ligand binding by FLAG- and Myc-tagged M6P/IGF2R mini-receptors via reciprocal co-immunoprecipitation

To test whether the FLAG or Myc epitope tags inter-fere with the formation of fully functional receptors in asymmetric heterodimers by having only half of the complex tethered to the resin, a reciprocal immunopre-cipitation was performed Cell lysates containing co-expressed FLAG and Myc epitope-tagged

mini-Transfected

construct

(µg)

1-15F

1-15F I/T

1-15Myc

1-15Myc I/T

30 0 0 0

15

15 0

0

15

15

0

0 0

0

15 15 15

15

0

0

0

0 0

30 30

0 0

0

IB: αα -FLAG

IB: α -FLAG

IB: α -Myc

IB: IP: α -Myc α -FLAG

IP: α -FLAG

C

D

E

F

B

A

Transfected

construct

(µg)

1-15F

1-15F I/T

1-15Myc

1-15Myc I/T

30 0 0 0

15

15 0

0

15

15

0 0 0

0

15 15 15

15

0

0

0

0 0

30 30

0 0

0

0

25

50

75

100

125

150

0

10

20

30

40

I-IGF-II binding c.p.m × 10

Fig 3 Co-immunoprecipitation and ligand binding by FLAG and Myc epitope-tagged asymmetric dimeric soluble receptors immuno-precipitated with M2 anti-FLAG resin The ability of 1-15Myc to co-immunoprecipitate with 1-15F was measured by immunoprecipi-tating equimolar amounts of the 1-15F soluble receptor with M2 anti-FLAG affinity resin from 293T lysates of the M6P ⁄ IGF2R mini-receptors After immunoprecipitation, the resin pellets were collected, washed, heated with sample buffer and analyzed by 6% reducing SDS ⁄ PAGE The proteins were transferred to BA85 nitro-cellulose, immunoblotted with anti-FLAG M2 (A, B) or anti-Myc 9E10 (C, D) Igs and developed with [ 125 I]protein A As a control, cell lysate in the amount that was used during the immunoprecipi-tation was directly loaded onto the gel (A, C) Cell lysates, contain-ing equimolar amounts of expressed FLAG-tagged soluble receptors, were immunoprecipitated with M2 anti-FLAG affinity resin and then incubated in the presence of 1 n M [ 125 I]PMP-BSA (E)

or 2 n M [ 125 I]IGF-II (F) for 3 h at 4 C Bound ligand was determined

by centrifuging the resin pellets, washing and counting the pellets

in a c-counter Radioactivity retained in the presence of either

5 m M Man-6-P or 1 l M IGF-II was subtracted from each binding reaction to determine the specific binding for [125I]PMP-BSA and [ 125 I]IGF-II, respectively The lines in each graph (E, F) indicate the amount of binding predicted if the wild-type and mutant receptors are binding ligand independently The tables indicate the amounts

of the various cDNAs transfected into cells for each condition and apply to the data shown both above and below the table Values represent the mean ± SD of three replicate measurements for each condition These data represent the means of four indepen-dent experiments [Correction added on 5 March 2009 after first online publication: in Fig 3D ‘IP: a-Myc’ was corrected to ‘IP: a-FLAG’, and in Fig 3F ‘125I-PMP-BSA binding’ was corrected to

‘ 125 I-IGF-II binding’.]

Trang 6

receptors were analyzed by an immunoprecipitation

assay using protein G-Sepharose and 9E10 anti-Myc

Ig Immunoblots revealed that essentially all of the

input Myc-tagged mini-receptors precipitated in the

assay (Fig 4A versus B) Figure 4C,D indicates that

approximately 50% of the co-expressed FLAG-tagged

mini-receptors were co-immunoprecipitated with the

Myc-tagged mini-receptors (Fig 4C versus D) As was

observed in anti-FLAG-based immunoprecipitations

(Fig 3), the presence of the I⁄ T mutation had no

effect on the interaction leading to

co-immunoprecipi-tation

To assess the ligand binding function of these asym-metric heterodimers, co-immunoprecipitated mini-receptors were subjected to direct binding analysis using radiolabeled ligands (Fig 4E,F) Based on the premise that only 75% of the dimers formed during this assay would be precipitable using the Myc-based immunoprecipitation, the amount of [125I]PMP-BSA binding was calculated and represented according to the line in the bar graph (Fig 4E) The data shown in Fig 4E for the co-immunoprecipitated mini-receptors were consistent with this expectation as well as the results observed with complementary anti-FLAG immunoprecipitation (Fig 3E)

Binding of [125I]IGF-II to immunoprecipitated mini-receptors was measured to determine whether IGF-II binds independently to both sides of the asymmetric hetero-oligomers (Fig 4F) It was projected that the percentage of binding would follow the line displayed

in the bar graph; however, when the I⁄ T mutant Myc-tagged mini-receptor served as the bait for immu-noprecipitation by the resin, binding of IGF-II to the asymmetric hetero-oligomers was interfered with or not detected as readily as expected These results are consistent with the results observed with anti-FLAG immunoprecipitation from the same panel of mini-receptor transfections (Fig 3F) It appeared that, no matter which epitope tag of the hetero-oligomer was

A

B

C

D

1-15F

1-15F I/T

1-15Myc

1-15Myc I/T

0 0 30 0

15

15 0

0

0

0

15 15 15

15

0 0 15

15

0

0

0

0 0

30 0

30 0

0

E

F

1-15F

1-15F I/T

1-15Myc

1-15Myc I/T

30 0 0

0

15

15 0

0

15 15 0

0

0 0 15

15 15

15

0

0 0

0 0

30 30

0 0

0

0

10

20

30

40

50

0

10

20

30

40

50

60

70

80

90

Transfected

construct

(µg)

Transfected

construct

(µg)

IB: α -Myc

IB: α -Myc IP: α -Myc

IB: α -FLAG IB: α -FLAG IP: α -Myc

I-IGF-II binding c.p.m × 10

Fig 4 Co-immunoprecipitation and ligand binding of FLAG and Myc epitope-tagged asymmetric dimeric soluble receptors immuno-precipitated with protein G-Sepharose The ability of 1-15F to co-immunoprecipitate with 1-15Myc was measured by immunopre-cipitating equimolar amounts of the 1-15Myc soluble receptor in 293T lysates of the M6P ⁄ IGF2R mini-receptors with protein G-Sepharose previously incubated with anti-Myc 9E10 Ig After immunoprecipitation, the resin pellets were collected, washed, heated with sample buffer and analyzed by 6% reducing SDS ⁄ PAGE The proteins were transferred to BA85 nitrocellulose and immunoblotted with anti-Myc 9E10 (A, B) or anti-FLAG M2 (C, D) Igs As a control, cell lysate in the amount that was used during the immunoprecipitation was directly loaded onto the gel (A, C) Cell lysates, containing equimolar amounts of expressed Myc-tagged soluble receptors, were immunoprecipitated with pro-tein G-Sepharose previously incubated with anti-Myc 9E10 Ig and assayed for binding of [ 125 I]PMP-BSA (E) or [ 125 I]IGF-II (F) The lines

in each graph (E, F) indicate the amount of binding predicted if the wild-type and mutant receptors are binding ligand independently The tables indicate the amounts of the various cDNAs transfected into cells for each condition and apply to the data shown both above and below the table Values represent the mean ± SD of three representative measurements for each condition These data represent the means of four independent experiments [Correction added on 5 March 2009 after first online publication: in Fig 4D ‘IP: a-FLAG’ was corrected to ‘IP: a-Myc’, and in Fig 4F ‘ 125 I-PMP-BSA binding’ was corrected to ‘ 125 I-IGF-II binding’.]

Trang 7

anchored to the immunoprecipitating resin, IGF-II

binding was suppressed when the tethering partner

(bait) was the I⁄ T mutant To test the possibility that

properties of the Myc epitope tag might somehow be

responsible for this phenomenon, the effects of a

different epitope tag, hemagglutinin (HA), were exam-ined in pairing with FLAG-tagged receptors However, these results (data not shown) were consistent with the results obtained with FLAG- and Myc-tagged partners (Fig 3F), even though a different epitope tag (HA instead of Myc) was combined with the FLAG epitope tag

Ligand binding by double-mutant, FLAG-tagged M6P/IGF2R mini-receptors

Two forms of the FLAG-tagged mini-receptors, 1-15 wild-type and 1-15 R426A⁄ R1325A (R2A), were con-structed to assess the possibility of intersubunit effects for the phosphomannosyl ligand binding sites of the mini-receptors (Fig 5A) These mini-receptors were transiently expressed alone or co-expressed in 293T cells Cell extracts were analyzed for relative expression levels of the mini-receptors by immunoblotting with M2 anti-FLAG Ig (data not shown)

Binding of [125I]IGF-II by immunoprecipitated wild-type versus R2A mutant mini-receptors was inde-pendent of the proportion of wild-type to mutant mini-receptors in the mixture, suggesting that the R2A mutation did not disrupt IGF-II binding (Fig 5B) These data support the hypothesis that IGF-II binding

to the co-immunoprecipitated mini-receptors would be almost the same as that observed with the mini-recep-tors expressed individually Binding of [125I]PMP-BSA

to immunoprecipitated mini-receptors was measured to assess whether the presence of the mutant recep-tors affected PMP-BSA binding to the wild-type mini-receptors (Fig 5C) In these experiments, the null hypothesis proposes that there is no cross-talk between binding sites within the mixture and thus binding should simply reflect the proportions of wild-type and mutant receptors in the transfection panel Thus, we projected that the percentage of binding based on contributions of the mutant (no binding activity) and wild-type (100% binding activity) mini-receptors in the mixture would follow the line displayed in the bar graph, suggesting that the wild-type binding site on one receptor is not affected by the presence of a mutant mini-receptor that is incapable of binding PMP-BSA

Ligand binding by double-mutant FLAG and Myc-tagged co-immunoprecipitated M6P/IGF2R mini-receptors

Two forms of the Myc epitope-tagged mini-receptors, 1-15 wild-type and 1-15 R426A⁄ R1325A (R2A) (Fig 6A), were constructed to assess whether these co-transfected differentially tagged mini-receptors can

Construct name:

FLAG FLAG

COOH COOH

* 1-15F R2A H 2 N

A

*

0 30

0 30

B

C

0.0 2.5 5.0 7.5 10.0 12.5 15.0

0 10 20 30 40

I-IGF-II binding c.p.m × 10

µg 1-15F cDNA

µg 1-15F R2A cDNA

Fig 5 Schematic diagram and ligand binding analysis of soluble

1-15 and 1-15R2A mutant FLAG epitope-tagged receptors

immuno-precipitated with anti-FLAG resin (A) The receptor constructs are

shown in linear format from the amino terminus to the carboxyl

terminus, with repeats of the ectodomain illustrated as rectangles.

The stippled rectangles represent repeat 11 containing the principal

residues responsible for IGF-II binding The shaded rectangles

indi-cated repeats 3 and 9, to which the main determinants of Man-6-P

binding have been mapped and the asterisk denotes the RfiA

mutations at residues 426 and 1325 (R2A), which abrogates

Man-6-P binding The black rectangles represent the FLAG epitope tags

on the carboxyl terminus (B, C) Cell lysates, containing equimolar

amounts of expressed soluble receptors, were immunoprecipitated

with M2 anti-FLAG affinity resin and assayed for binding of

[ 125 I]IGF-II (B) or [ 125 I]PMP-BSA (C) The lines in each graph indicate

the amount of binding predicted if the wild-type and mutant

recep-tors are binding ligand independently The triangles indicate a

progressive shift in the ratio of wild-type to mutant receptor cDNA

transfected into cells Values represent the mean ± SD of three

replicate measurements for each condition These data represent

the means of four independent experiments.

Trang 8

be immunoprecipitated as oligomeric complexes These

mini-receptors were transiently expressed alone or

co-expressed in 293T cells, and analyzed for relative

expression levels of the mini-receptors by

immuno-blotting with anti-FLAG and anti-Myc Igs (data not

shown)

The cell lysates with volumes normalized for

expres-sion of the FLAG-tagged mini-receptor were analyzed

by an immunoprecipitation assay using M2

anti-FLAG affinity resin PhosphorImager analysis of the

immunoblots confirmed that essentially all of the

expressed FLAG-tagged mini-receptors precipitated by incubation with the M2 affinity resin (Fig 6B versus C) The data shown in Fig 6D,E indicate that approx-imately 50% of the co-expressed Myc-tagged mini-receptors were co-immunoprecipitated with the FLAG-tagged mini-receptors (Fig 6D versus E), suggesting a balanced distribution between Myc-tagged mini-receptor homo-oligomers and hetero-oligomers with the FLAG-tagged mini-receptors The presence of the R2A mutation had no detectable effect on the interaction leading to co-immunoprecipitation

Binding of [125I]IGF-II to immunoprecipitated wild-type versus R2A mutant mini-receptors was equivalent, suggesting that the R2A mutation had no discernible effect on the formation of oligomers that are func-tional in IGF-II binding (Fig 6F) These data were consistent with the prediction that, because 25% of the oligomers formed should be homo-oligomers of Myc-tagged mini-receptors, IGF-II binding by the co-immu-noprecipitated mini-receptors should have yielded approximately 75% of the binding observed with

1-15F

1-15F R2A

1-15Myc

1-15Myc R2A

30

0 0 0

15

15 0

0 15

15

0 0 0

0

15 15 30

0

0

0 0

0 30 0

0

0 0 30

Myc Myc

COOH COOH

1-15Myc

A

B

C

D

E

1-15F

1-15F R2A

1-15Myc

1-15Myc R2A

30 0 0 0

15

15 0

0 15

15

0 0 0

0

15 15 30

0

0

0 0

0 30 0

0

0 0 30

F

G

0

25

50

75

100

125

0

100

200

300

400

500

600

700

800

IB: α -FLAG

IB: α -FLAG IP: α -FLAG Transfected

construct

(µg)

Transfected

construct

(µg)

IB: α -Myc

IB: IP: α -Myc α -FLAG

I-IGF-II binding c.p.m × 10

Fig 6 Schematic diagram of soluble 1-15 and 1-15 R2A mutant Myc epitope-tagged receptors, co-immunoprecipitation and ligand binding analysis of soluble 1-15 and 1-15R2A mutant FLAG and Myc epitope-tagged asymmetric soluble heterodimeric receptors (A) The receptor constructs are shown in linear format from amino terminus to carboxyl terminus, with repeats of the ectodomain illus-trated as rectangles The stippled rectangles represent repeat 11 containing the principal residues responsible for IGF-II binding The shaded rectangles indicated repeats 3 and 9, to which the main determinants of Man-6-P binding have been mapped and the aster-isk denotes the RfiA mutations at residues 426 and 1325 (R2A), which abrogates Man-6-P binding The black rectangles represent the Myc epitope tags on the carboxyl terminus (B–E) The ability of 1-15Myc to co-immunoprecipitate with equimolar amounts of 1-15F soluble receptor with M2 anti-FLAG affinity resin from 293T cell lysates of M6P ⁄ IGF2R mini-receptors After immunoprecipitation, the resin pellets were collected, washed and immunoblotted with anti-FLAG M2 (B, C) or anti-Myc 9E10 (C, D) Igs As a control, cell lysate in the amount that was used during the immunoprecipitation was directly loaded on the gel (B, D) (F, G) Cell lysates, containing equimolar amounts of expressed FLAG-tagged soluble receptors, were immunoprecipitated with M2 anti-FLAG affinity resin and assayed for binding of 2 n M [ 125 I]IGF-II (F) or 1 n M [ 125 I]PMP-BSA (G) for 3 h at 4 C The lines in each graph (F, G) indicate the amount of binding predicted if the wild-type and mutant receptors are binding ligand independently The tables indicate the amounts

of the various cDNAs transfected into cells for each condition and apply to the data shown both above and below the table Values represent the mean ± SD of three replicative measurements for each condition These data represent the means of four indepen-dent experiments [Correction added on 5 March 2009 after first online publication: in Fig 6E ‘IP: a-Myc’ was corrected to ‘IP: a-FLAG’, and in Fig 6F ‘ 125 I-PMP-BSA binding’ was corrected to

‘125I-IGF-II binding’.]

Trang 9

individually immunoprecipitated, FLAG-tagged

mini-receptors

Binding of [125I]PMP-BSA to these asymmetric

het-ero-oligomers was measured to determine whether

PMP-BSA binding would show interactive effects

between the wild-type and mutant partners (Fig 6G)

As observed previously when a mutant FLAG-tagged

mini-receptor acted as the bait molecule in the

immu-noprecipitation, binding of PMP-BSA to the

asym-metric hetero-oligomers was suppressed These results

are consistent with the results obtained in experiments

with the I⁄ T mutation, suggesting that the ligand

bind-ing functions of the receptor’s ectodomain can operate

independently of one other within each receptor and

relative to receptor partners, again indicating that this

effect depends on tethering the C-terminal ends of the

extracytoplasmic domains

Discussion

The rationale for the present study was to improve

understanding of how the subunits of the multimeric

M6P⁄ IGF2R participated in binding the two main

classes of ligands, IGF-II and phosphomannosylated

glycoproteins In mammals, binding of IGF-II by the

M6P⁄ IGF2R is thought to contribute to growth

homeostasis Previous studies have shown that

the receptor operates optimally as a dimer and, in the

present study, we aimed to determine what effect the

dimeric structure may have on IGF-II binding It has

been suggested that IGF-II binding to the

M6P⁄ IGF2R requires contributions of repeats 11 and

13, but only within a single polypeptide chain

[20,22,33] It is well established that the receptor binds

Man-6-P ligands in a multivalent fashion [1,18,35]

However, because the receptor has two Man-6-P

bind-ing domains within a sbind-ingle polypeptide chain, it

remains uncertain whether this bivalent binding

activ-ity is a property of a single monomeric receptor or the

result of cooperative interaction between the two

subunits of a dimeric receptor There is strong evidence

that, in the cell, the preferred mode of binding is

through a dimeric structure, as shown by York et al

[24], who found that a multivalent

phosphomannosy-lated ligand cross-bridged the dimeric receptor to

pro-mote optimal internalization This conclusion was

reinforced by Byrd et al [34], who analyzed mutant

receptors bearing a substitution of Arg for Ala at

posi-tion 1325 that knocks out Man-6-P ligand binding to

the repeat 9 site Scatchard plot analysis showed that

these mutant receptors were still able to bind bivalent

Man-6-P ligands with high-affinity, leading to the

con-clusion that high-affinity binding in that case must be

due to alignment of two repeat 3 Man-6-P binding domains on paired monomers Furthermore, Olson

et al [16] demonstrated, via X-ray projection models, that the closest distance between the two Man-6-P binding sites of one monomeric receptor is 45–70 A˚, indicating that a single diphosphorylated oligosaccha-ride, with a maximum distance of approximately 30 A˚ [35], could not bind to the Man-6-P binding domains

of both repeats 3 and 9 simultaneously [16] The pres-ent study was designed to test whether ligand binding

by the dimeric receptor is cooperative, based on the hypothesis that IGF-II binds independently to cognate sites on both monomers of the dimeric receptor, but that Man-6-P ligand binding would require coopera-tion of both monomers For this purpose, we devel-oped a quantitative assay for heterodimer formation that was based on immunoprecipitation of differen-tially epitope-tagged receptors The availability of the I1572T mutant allowed us to address the initial question of whether a nonfunctional IGF-II binding site would interfere with the function of a wild-type binding site when paired in a single heterodimeric structure

Association assays indicated that immunoprecipita-tion between differentially epitope-tagged mini-recep-tors was feasible These assays also indicated that immunoprecipitation was not preferential to the epitope used to tag the receptor because there was no discernable difference between the Myc- and HA-tagged receptors in co-immunoprecipitation with the FLAG-tagged receptor As expected, we observed that essentially all of the FLAG-tagged mini-receptors were precipitated by incubation with M2 resin In experiments with the FLAG-tagged receptor as the bait, approximately 50% of the Myc-tagged mini-receptors were co-precipitated from a cell lysate pre-pared from cells co-transfected with equal amounts of the tagged mini-receptor cDNA This strongly sug-gests, but does not prove, that the mini-receptors asso-ciated in a 1 : 2 : 1 relationship: 25% FLAG homodimers, 50% FLAG-Myc heterodimers and 25% Myc homodimers (which would not precipitate in this assay) The simplest interpretation of these data rela-tive to the structure of the receptor is that the mini-receptors were in the form of dimers Byrd et al [34] showed, via mutational analysis, that receptors with only one functional Man-6-P binding site exhibited high-affinity binding of Man-6-P-containing ligands Given that high-affinity binding of a bivalent ligand is due to cooperative interaction with two or more recep-tor binding sites [35], these data suggested that oligo-merization of the receptor contributes to high-affinity binding In addition, native gel electrophoresis

Trang 10

demon-strated that the receptor could be separated into

monomeric and dimeric forms in the presence or

absence of Man-6-P-containing ligands [25] York

et al [24] demonstrated, by sucrose gradient

sedimen-tation and gel filtration, that the receptor bound to a

multivalent Man-6-P-containing ligand,

b-glucuroni-dase, exhibited a sedimentation coefficient and Stokes

radius that were consistent with a complex of two

receptor molecules plus one molecule of ligand

How-ever, when these experiments were performed with

IGF-II, the receptor appeared to exist as a monomer

Internalization experiments performed with [125

I]IGF-II in the presence of b-glucuronidase revealed that

b-glucuronidase accelerated the rate of IGF-II uptake,

suggesting that intermolecular cross-linking of

recep-tors enhanced receptor endocytosis [24] Thus, all the

available data are consistent with the conclusion that

the M6P⁄ IGF2R functions as a dimer in high-affinity

binding of Man-6-P-bearing ligands, but possibly not

for IGF-II The present study, employing soluble

forms of the receptor [25,26,34], indicates that the

ectodomain of the receptor is capable of dimer

forma-tion in the absence of ligand

Affinity cross-linking of [125I]IGF-II to a mutant

repeat 11 mini-receptor revealed that the I1572T

muta-tion completely abolished IGF-II binding [31] This

finding was confirmed by Linnell et al [22] by utilizing

surface plasmon resonance of a truncated receptor

containing extracytoplasmic repeats 10–13, which

con-tained the I1572T mutation in repeat 11 However, the

mechanism by which this mutation abrogates IGF-II

binding is still not clear Structural analysis of repeat

11 identified the presumptive IGF-II binding site in a

hydrophobic pocket at the end of a b-barrel structure

[36] Ile1572 was found to lie near, but not directly

within, this putative IGF-II binding site This mutation

involves substituting a polar residue, Thr, for a bulky,

nonpolar residue, Ile, which might have altered the

IGF-II binding pocket by inducing a conformational

change that reduces binding energy or makes the site

less hydrophobic In any case, this type of effect

should be regional and have minimal influence on the

wild-type IGF-II binding site on an adjacent

mini-receptor within a dimer Our experiments support this

prediction, showing that the pairing of wild-type and

11572T mutant IGF-II binding sites between two

dimerized mini-receptors had no effect on the function

of the contralateral binding site The mutant site does

not prevent the wild-type site from binding IGF-II and

pairing with a wild-type subunit does not repair the

defect in the mutant site inducing it to bind IGF-II

This indicates that IGF-II binding to each side of the

dimer is independent Symmetric heterodimers (i.e

having identical epitope tags, both of which are teth-ered to the resin bead) achieve the predicted amount

of binding as described above Tethering of both sides

of the dimer likely mimics the structure obtained when anchored in the membrane, in accordance with the notion that this structure is the receptor’s normal func-tional state

The most interesting and unexpected finding of the present study is that asymmetric heterodimers (i.e hav-ing different epitope tags, of which only one is tethered

to the resin bead) demonstrate complex binding behavior Dimers of this type exhibit the predicted amount of binding only if the heterodimer is tethered

by the wild-type partner By contrast, we found that, if the heterodimer is tethered to the resin by the mutant partner, the amount of binding observed is substan-tially less than expected This complex binding behav-ior observed with IGF-II binding must only be a local effect because binding of PMP-BSA, which binds to other sites in the ectodomain of these heterodimers, resulted in the predicted amount of ligand binding This loss of binding function observed with asym-metric heterodimers may be due to deformation of the dimeric structure One possible explanation for failure

to form a dimer of correct structure could be steric hindrance between the Myc tag and the M2 resin bead This is envisioned to cause the Myc-tagged receptor partner to be bent outward away from the tethered FLAG-tagged partner, potentially resulting in distor-tion of the IGF-II binding pocket and a consequent reduced ability to bind IGF-II This effect is likely not due to reduced contact between repeats 11 and 13 because repeat 11 is capable of binding IGF-II even in the absence of repeat 13 [20,22] These data suggest that the failure to tether the tail of the extracyto-plasmic domain results in the inability to form appro-priate contacts between dimeric partners Follow-up experiments using structural approaches are required

to address this possibility

Localization of the two Man-6-P binding domains was previously reported by Westlund et al [30], who subjected the M6P⁄ IGF2R to partial proteolytic diges-tion using subtilisin They determined that repeats 1–3 and 7–10 can independently bind Man-6-P-containing ligands Dahms et al [19] further defined the location

of Man-6-P binding sites by using mutational analysis

to establish the importance of specific Arg residues in the function of both Man-6-P binding sites They determined that Arg426 and Arg1325 in repeats 3 and

9, respectively, are essential components of the recep-tor’s high-affinity Man-6-P binding sites The structure

of repeats 1–3 of the bovine M6P⁄ IGF2R in the pres-ence of Man-6-P was solved by Olson et al [18] Their

Ngày đăng: 18/02/2014, 08:20

TỪ KHÓA LIÊN QUAN

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm